Drug intelligence / Profile preview

epirubicin + erythropoietin

Development stage: Unknown
Lead developer: Amgen
Modality: Recombinant Proteins and Enzymes, Small Molecules
Administration: Intravenous, Intravesical

Overview

A combination therapy consisting of epirubicin, an anthracycline chemotherapy agent, and erythropoietin, a glycoprotein hormone that stimulates red blood cell production. Epirubicin works by intercalating between DNA base pairs, inhibiting topoisomerase II activity, and interfering with DNA replication and transcription, which damages cancer cells and prevents them from dividing or growing. Erythropoietin is administered alongside epirubicin-containing chemotherapy regimens to prevent or treat chemotherapy-induced anemia by stimulating the production of red blood cells in the bone marrow.

Targets

TOP2A (DNA topoisomerase II)DNAErythropoietin Receptor

Beyond the preview

Go deeper on epirubicin + erythropoietin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on epirubicin + erythropoietin.

Explore the full profile